Back to News
Market Impact: 0.25
Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026
Source: globenewswire.com
Healthcare & Biotech
In the Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood-pressure reductions in participants with and without chronic kidney disease (CKD), with consistent reductions across CKD stages 1–3. The report provides no numerical effect size or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
- Moderna shares plunge after leak of partial cancer vaccine data
- Palmer Luckey teams with dire wolf billionaire Ben Lamm to launch $200 million Warhound, unleashing genetically engineered clone dogs of war
- Moderna's stock tumbles after reported leak of data for cancer vaccine
- Zai Lab raises $250 million in private placement financing
- Moderna Stock Sinks Nearly 20% After Leak of Cancer-Vaccine Data
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Research Tools for Pension Funds and Allocators
- AllMind's Data Standardization Methodology: Our Approach to Fundamentals